Trial Profile
A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs PNT 2003 (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 12 Jan 2023 According to Point Biopharma media release, the company has recently received the clinical trial data sets of this study where in Point Biopharma will facilitate the analysis of data sets and Lantheus will prepare and submit the regulatory filings in the USA.
- 14 Nov 2022 According to a Lantheus Holdings media release, Lantheus and POINT Biopharma has announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT's PNT2002 and PNT2003 product candidates. POINT will facilitate completion of this study.
- 07 Apr 2022 Planned End Date changed from 1 Jan 2024 to 1 Jun 2026.